Register Interest

EpiAxis Therapeutics

EpiAxis Therapeutics is a private company developing a pipeline of epigenetic cancer treatments, leading with LSD1 inhibitors. The lead indication is metastatic breast cancer with later extension to many other tumor types, offering significant commercial potential. EpiAxis is undertaking IND-enabling studies for a first-in-human study to commence late 2022. Importantly, the Company has a highly competent management team in place.